Platelets and soluble fibrin promote plasminogen activation causing downregulation of platelet glycoprotein Ib/IX complexes: Protection by aprotinin

Thrombosis Research

Volumn 92, Issue 4, 1998, Pages 171-179

  De Haan, Jacob ^a   Van Oeveren, Willem ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Cardiopulmonary bypass; Fibrinolysis; Glycoprotein Ib IX; Hemostasis; Platelets; Soluble fibrin

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTIFIBRINOLYTIC AGENT; APROTININ; FIBRIN; PLASMIN; PLASMINOGEN; THROMBIN RECEPTOR; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID;

ARTICLE; BLEEDING; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HUMAN CELL; OPEN HEART SURGERY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; THROMBOCYTE MEMBRANE; THROMBOCYTE METABOLISM;

ANTIBODIES, MONOCLONAL; ANTIFIBRINOLYTIC AGENTS; ANTIPLASMIN; APROTININ; BLOOD PLATELETS; DOWN-REGULATION; FIBRIN; FIBRINOLYTIC AGENTS; HUMANS; PLASMIN; PLASMINOGEN; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID;

EID: 0032533422     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00130-3     Document Type: Article

References (33)

1. Ratnatunga C.P., Rees G.M., Kovacs I.B. Preoperative hemostatic activity and excessive bleeding after cardiopulmonary bypass. Ann Thorac Surg. 52:1991;250-257.
2. Harker L.A., Malpass T.W., Branson H.E., Hessell E.A. II, Slichter S.J. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass. Acquired transient platelet dysfunction associated with alpha-granule release Blood. 56:1980;824-834.
3. Zilla P., Fasol R., Groscurth P., Klepetko W., Reichenspurner H., Wolner E. Blood platelets in cardiopulmonary bypass operations. Recovery occurs after initial stimulation, rather than continual stimulation J Thorac Cardiovasc Surg. 97:1989;379-388.
4. Tabuchi N., de Haan J., van Oeveren W. Rapid recovery of platelet function after cardiopulmonary bypass. Blood. 82:1993;2930-2931.
5. Oeveren van W., Harder H.P., Roozendaal K.J., Eijsman L., Wildevuur Ch.R.H. Aprotinin protects platelets against the initial effect of card iopulmonary bypass. J Thorac Cardiovasc Surg. 99:1990;788-797.
6. Sakariassen K.S., Nievelstein P.F., Coller B.R., Sixma J.J. The role of platelet membrane glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium. Br J Haematol. 63:1986;681-691.
7. Stibbe J., Kluft C., Brommer E.J.P., Gomes M., Jong de D.S., Nauta J. Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest. 14:1984;375-382.
8. van Oeveren W., Eysman L., Roozendaal K.J., Wildevuur C.R. Platelet preservation by aprotinin during cardiopulmonary bypass. Lancet. 19:1988;644.
9. Bidstrup B.P., Royston D.R., Sapsford R.N., Taylor K.M. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose of aprotinin (Trasylol®). J Thorac Cardiovasc Surg. 97:1989;364-372.
10. Blauhut B., Gross C., Necek S., Doran J.E., Späth P., Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 101:1991;958-967.
11. Horrow J.C., Hlavacek J., Strong M.D., Collier W., Brotsky I., Goldman S.M., Goel I.P. Prophylatic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg. 99:1990;70-74.
12. Van der Salm T.J., Ansell J.E., Okike O.N., Marsicano T.H., Lew R., Stephenson W.P., Rooney K. The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation. A double blind randomized study J Thorac Cardiovasc Surg. 95:1988;538-540.
13. De Haan J., Schönberger J.P.A.M., Haan J., van Oeveren W., Eijgelaar A. Tissue-type plasminogen activator and fibrin monomers synergistically cause platelet dysfunction during retransfusion of shed blood after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 106:1993;1017-1023.
14. Hogg P.J., Jackson C.M. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin II. implications for heparin efficacy Proc Natl Acad Sci USA. 86:1989;3619-3623.
15. Achyuthan K.E., Dobson J.V., Greenberg C.S. Gly-Pro-Arg-Pro modifies the glutamine residues in the alpha- and gamma-chains of fibrinogen. Inhibition of transglutaminase cross-linking Biochim Biophys Acta. 872:1986;261-268.
16. Wiman B., Rånby M. Determination of soluble fibrin in plasma by a rapid and quantative spectrophotometric assay. Thromb Haemost. 55:1986;189-193.
17. Hemmilâ I., Dakubu S., Mukkala V-M Siitari H., Lovgren T. Europium as a label in time-resolved immunofluorometric assays. Anal Biochem. 137:1984;335-343.
18. Stricker R.B., Wong D., Shiu D.T., Reyes P.T., Shuman M.A. Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets. Effects on surface proteins and platelet aggregation Blood. 68:1986;275-280.
19. Hantgan R. Fibrin protofibril and fibrinogen binding to ADP-stimulated platelets. Evidence for a common mechanism Biochim Bioph Acta. 968:1988;24-35.
20. Hörmann H., Richter H., Jelinić V. Free N-terminal fibronectin 30-KD-domain mediates binding of soluble fibrin to gelfiltered unstimulated thrombocytes. Thromb Res. 51:1988;283-293.
21. Miles L.A., Ginsberg M.H., White J.G., Plow E.F. Plasminogen interacts with human platelets through two distinct mechanisms. J Clin Invest. 77:1986;2001-2009.
22. Miles L.A., Plow E.F. Binding and activation of plasminogen on the platelet surface. J Biol Chem. 260:1985;4303-4311.
23. Peerschke E.I.B. Stabilization of platelet-fibrinogen interactions. Modulation by divalent cations J Lab Clin Med. 135-41:1993.
24. Ginsberg M.H., Lightsey A., Kunicki T.J., Kaufmann A., Marguerie G., Plow E.F. Divalent cation regulation of the surface orientation of platelet membrane glycoprotein IIb. Correlation with fibrinogen binding function and defenition of a novel variant of Glanzmann's thrombasthenia. J Clin Invest. 78:1986;1103-1111.
25. Pidard D., Didry D., Kunicki T.J., Nurden A.T. Temperature-dependent effects of EDTA on the membrane glycoprotein IIb-IIIa complex and platelet aggregability. Blood. 67:1986;604-611.
26. Shigeta U., Kojima H., Jikuya T., Terada Y., Atsumi N., Sakakibara Y., Nagasawa T., Mitsui T. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. Circulation. 96:1997;569-574.
27. Niewiarowski S., Senyi A.F., Gillies P. Plasmin-induced platelet aggregation and platelet release reaction. J Clin Invest. 52:1973;1647-1659.
28. Ehrlich H.J., Klein Gebbink R., Preissner K.T., Keijer J., Esmon N.L., Mertens B.J., Pannekoek H. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix. J Cell Biol. 115:1991;1773-1781.
29. Levin E.G., Santell L. Stimulation and desensitization of tissue plasminogen activator release from human endothelial cells. J Biol Chem. 263:1988;9360-9365.
30. Tappy L., Hauert J., Bachman F. Effects of hypoxia and acidosis on vascular plasminogen activator release in the pig ear perfusion system. Thromb Res. 33:1984;117-124.
31. Tabuchi N., de Haan J., Boonstra P.W., van Oeveren W. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 106:1993;828-833.
32. Wenger R.K., Lukasiewicz H., Mikuta B.S., Niewiarowski Edmunds L.H. Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg. 97:1989;235-239.
33. Michelson A.D., Barnard M.R. Plasmin-induced redistribution of platelet glycoprotein Ib. Blood. 76:1990;2005-2010.